

October 24, 2017



## Ligand to Report Third Quarter 2017 Results on November 9th

SAN DIEGO--(BUSINESS WIRE)-- **Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)** announced today that it plans to report third quarter 2017 financial results after market close on November 9, 2017 and to provide additional commentary during its Analyst Day, which will take place on November 14, 2017 from 4:00 p.m. to 5:30 p.m. Eastern time (1:00 p.m. to 2:30 p.m. Pacific time) in New York City. As such, Ligand will not be hosting an earnings conference call this quarter.

The Analyst Day event will be webcast live at [www.ligand.com](http://www.ligand.com) and a replay will be available for 90 days following the event. For more information or to reserve a seat, please contact Ani Mikaelian at [amikaelian@lhai.com](mailto:amikaelian@lhai.com).

### About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue. Ligand's Captisol<sup>®</sup> platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. OmniAb<sup>®</sup> is a patent-protected transgenic animal platform used in the discovery of fully human mono- and bispecific therapeutic antibodies. Ligand has established multiple alliances, licenses and other business relationships with the world's leading pharmaceutical companies including Novartis, Amgen, Merck, Pfizer, Celgene, Gilead, Janssen, Baxter International and Eli Lilly.

Follow Ligand on Twitter @Ligand\_LGND.

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20171024006509/en/>

Ligand Pharmaceuticals Incorporated

Todd Pettingill

(858) 550-7500

[investors@ligand.com](mailto:investors@ligand.com)

@Ligand\_LGND

or

LHA

Bruce Voss

(310) 691-7100

[bvoss@lhai.com](mailto:bvoss@lhai.com)

Source: Ligand Pharmaceuticals Incorporated